Welcome to our dedicated page for Small Pharma news (Ticker: DMTTF), a resource for investors and traders seeking the latest updates and insights on Small Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Small Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Small Pharma's position in the market.
Small Pharma Inc. (TSXV: DMT, OTCQB: DMTTF) has appointed Mr. Paul Maier as a non-executive independent director and Chair of the Compensation Committee. With over 30 years in the biopharmaceutical sector, Maier brings significant expertise, having raised over US$1.5 billion and served in prominent roles at U.S. biotech firms. His addition is expected to enhance the Board's financial capabilities during a critical growth phase as the company advances its clinical programs, including a Phase I/IIa trial of DMT-assisted therapy for mental health.
Small Pharma has confirmed positive discussions with the FDA regarding the U.S. component of its Phase IIb clinical trial for SPL026, a DMT-assisted therapy aimed at treating major depressive disorder (MDD). The FDA provided guidance on trial design and manufacturing considerations, facilitating the inclusion of U.S. sites alongside European and U.K. locations. Small Pharma believes this could be the first clinical trial of DMT-assisted therapy for MDD, offering an innovative treatment option for patients.
LONDON, Nov. 12, 2021 - Small Pharma (TSXV: DMT, OTCQB: DMTTF) announces attendance at the LSX Inv€$tival Showcase and Jefferies London Healthcare Conference. The CEO, Peter Rands, and Chief Medical Officer, Dr. Carol Routledge, will present a webcast on DMT-assisted therapy for Major Depressive Disorder, available on-demand. Small Pharma will hold in-person meetings on November 15 and from November 16-19 in London. The company focuses on developing DMT-based therapies for mental health conditions, aiming to advance the world's first clinical trial for MDD in collaboration with Imperial College London.
Small Pharma has successfully completed its Phase I clinical trial for SPL026, a DMT-assisted therapy aimed at treating Major Depressive Disorder (MDD). Dosing for the Phase IIa trial has begun, with topline results expected in H1 2022. The company has received a fast-track Innovation Passport Designation from the MHRA and upgraded to the OTCQB market. Financially, it reports $50.3 million in cash and increased operating expenses of $8 million for the six months ended August 31, 2021. Small Pharma is focused on advancing its clinical trials and expanding its patent portfolio, now holding three granted patents with 41 applications pending.
Small Pharma has received European patent grant EP 3 463 323 for oral dosage forms of its preclinical candidate SPL801B, a ketamine-based treatment for depression. The patent secures its commercial exploration and protects its innovative 6-HNK compounds. CEO Peter Rands emphasized this as a key step in progressing the company’s therapeutic pipeline. Preclinical studies suggest potential antidepressant effects without the psychoactive side effects of ketamine. This patent represents a significant addition to Small Pharma's intellectual property portfolio, enhancing its position in mental health treatment innovations.
Small Pharma Inc. (TSXV: DMT, OTCQB: DMTTF) has received MHRA Innovation Passport Designation for its lead candidate SPL026, aimed at treating major depressive disorder (MDD). This designation, akin to the FDA’s fast-track, allows for specialist guidance and enhances the development process of SPL026, which is currently in clinical trials. The Innovation Passport serves under the Innovative Licensing and Access Pathway (ILAP), expediting market entry and patient access to new treatments. Small Pharma is focused on DMT-assisted therapies with a robust development pipeline.
Small Pharma Inc. has successfully upgraded its trading status to the OTCQB Venture Market, allowing U.S. investors easier access to its shares under the symbol DMTTF. This transition follows a recent financing round that raised $58 million and comes as the company advances its clinical trials, particularly for its lead product, SPL026, targeting major depression. CEO Peter Rands expressed optimism about this development, which aims to enhance visibility and liquidity for investors in the growing mental health treatment landscape.
Small Pharma Inc. (TSXV: DMT) will present at Canaccord Genuity's 41st Annual Growth Conference on August 10, 2021, at 8:30 a.m. ET. The presentation will feature Peter Rands and Dr. Carol Routledge, accessible via a live webcast on their investor relations page. Small Pharma is advancing its lead candidate, SPL026, in a Phase I/IIa clinical trial for Major Depressive Disorder, with expected data readout in H1 2022. The company focuses on psychedelic-assisted therapies targeting mental health conditions.